Tirzepatide (40 mg)

What is Tirzepatide (40 mg)?

Tirzepatide (40 mg) is a synthetic peptide designed for advanced research in metabolic and endocrine pathways. This peptide functions as a dual agonist, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The ability to activate both receptors makes it a valuable tool for studying the integrated hormonal signaling pathways that govern metabolic processes and cellular responses.

Tirzepatide incorporates structural modifications, including α-aminoisobutyric acid (Aib) residues and a C20 fatty acid side-chain. These modifications enhance its molecular stability and allow prolonged receptor engagement, which is ideal for studying sustained signaling, unlike the rapid degradation of native incretin hormones.

The 40 mg format is optimized for extended experimental workflows, multi-phase studies, and research that requires consistent peptide supply and reproducibility. Tirzepatide (40 mg) is for laboratory research use only.

Product Specifications

• Synonyms: LY3298176, P1206, tirzepatida, tirzepatidum
• CAS Number: 2023788-19-2
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight:4813.48 g/mol g/mol
• Peptide Sequence:
  Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 40 mg lyophilized powder in a sealed research-grade vial
• Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Tirzepatide (40 mg)

• Dual incretin receptor–targeted peptide for metabolic signaling research
• Activates both GIP and GLP-1 receptors in experimental models
• Fatty acid (C20) side-chain modification enhances stability and prolongs receptor interaction
• Amino acid substitutions improve resistance to enzymatic degradation
• High purity verified using HPLC and mass spectrometry
• Supplied in lyophilized form to preserve molecular integrity before reconstitution
• Ideal for in vitro assays and preclinical metabolic research models

How Tirzepatide (40 mg) Supports Research

Tirzepatide (40 mg) is utilized in laboratory research to study dual incretin receptor signaling. By targeting both GIP and GLP-1 receptors, it enables researchers to assess coordinated intracellular signaling, such as cyclic AMP (cAMP) activation, and its effects on metabolic pathways.

In controlled experimental models, researchers study Tirzepatide to examine receptor binding dynamics, sustained signaling, and integrated hormonal communication related to energy metabolism. Its structural stability enables evaluation of prolonged receptor engagement and provides a basis for comparing dual receptor agonists with single-receptor peptides in metabolic research.

Research Applications & Usage Information

Tirzepatide (40 mg) is commonly applied in laboratory research for:

• Dual GIP and GLP-1 receptor signaling studies
• Glucose metabolism and endocrine communication research
• Energy balance and metabolic pathway modeling
• Cellular second-messenger and signal transduction analysis
• Comparative studies of incretin-based peptide analogs
• Preclinical metabolic disorder research models
• Hormone–receptor interaction and pharmacodynamic investigations

All applications are investigational and restricted to controlled laboratory research environments.

Handling and Storage Recommendations

• Store at 2–8 °C (≤–20 °C for long-term storage). Protect from light exposure.
• Keep vials tightly sealed and protected from moisture until reconstitution.
• Allow the vial to equilibrate before opening to minimize exposure to condensation.
• After reconstitution, store prepared solutions at 2–8 °C, as per laboratory protocol.
• Avoid repeated freeze-thaw cycles to support research applications.
• Use sterile laboratory techniques during preparation and experimentation.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
2. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009